Bayer AG operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Bayer AG with three other
pharmaceutical manufacturers in Europe:
sales of 46.58 billion Swiss Francs [US$51.24 billion]
of which 78%
was Innovative Medicines),
(37.37 billion Euros [US$45.13 billion]
of which 69%
was Pharmaceuticals), and
based in UNITED KINGDOM
(£34.10 billion [US$47.89 billion]
of which 50%
Bayer AG reported sales of 41.40 billion Euro (US$50.00 billion)
December of 2020.
decrease of 4.9%
versus 2019, when the company's sales were 43.55 billion Euro.
Contributing to the drop in overall sales was the 26.4% decline
in All Other Segments, from 277.00 million Euro to 204.00 million Euro.
There were also decreases in sales in
Cropscience (down 5.0% to 18.84 billion Euro)
Pharmaceuticals and Biological Products (down 4.0% to 17.24 billion Euro)
Consumer Care (down 7.5% to 5.05 billion Euro)
However, these declines were partially offset by the increase in sales of
Reconciliations (up 391.7% to 59.00 million Euro)